How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/cd20-positive-diffuse-large-b-cell-non-hodgkin-s-lymphoma.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

CD20 positive diffuse large B cell non Hodgkin's lymphoma — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CD20 positive diffuse large B cell non Hodgkin's lymphoma (disease) competitive landscape: 3 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

3 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating CD20 positive diffuse large B cell non Hodgkin's lymphoma, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Mabthera	rituxan	Roche	CD20-directed Cytolytic Antibody	B-lymphocyte antigen CD20	1997-01-01
Mabthera	Rituximab-Pvvr	Roche	Monoclonal antibody	CD20 antigen on pre-B and mature B-lymphocytes	1997-01-01
Mabthera	rituximab	Roche	CD20-directed Cytolytic Antibody [EPC]	B-lymphocyte antigen CD20	1997-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Roche · 3 drugs in CD20 positive diffuse large B cell non Hodgkin's lymphoma

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in CD20 positive diffuse large B cell non Hodgkin's lymphoma:

Cite this brief

Drug Landscape (2026). CD20 positive diffuse large B cell non Hodgkin's lymphoma — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/cd20-positive-diffuse-large-b-cell-non-hodgkin-s-lymphoma. Accessed 2026-06-10.

CD20 positive diffuse large B cell non Hodgkin's lymphoma full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing